(19)
(11) EP 2 570 415 A8

(12) CORRECTED EUROPEAN PATENT APPLICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 A1)

(48) Corrigendum issued on:
22.05.2013 Bulletin 2013/21

(43) Date of publication:
20.03.2013 Bulletin 2013/12

(21) Application number: 11306179.0

(22) Date of filing: 19.09.2011
(51) International Patent Classification (IPC): 
C07D 487/04(2006.01)
A61P 19/02(2006.01)
 A61K 31/4985(2006.01)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(71) Applicant: SANOFI
75008 Paris (FR)

(72) Inventors:
  • Nazaré, Marc
    65926 Frankfurt am main (DE)
  • Halland, Nis
    65926 Frankfurt am main (DE)
  • Schmidt, Friedemann
    65926 Frankfurt am main (DE)
  • Weiss, Tilo
    65926 Frankfurt am main (DE)
  • Dietz, Uwe
    65926 Frankfurt am main (DE)
  • Hofmeister, Armin
    65926 Frankfurt am main (DE)

(74) Representative: Kujath, Eckard et al
Sanofi-Aventis Deutschland GmbH Patent- und Lizenzabteilung Industriepark Höchst Gebäude K 801
65926 Frankfurt am Main
65926 Frankfurt am Main (DE)

   


(54) N-[4-(1H-Pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals


(57) The present invention relates to N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides of the formula I,

wherein Ar, R1, R2 and n have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds which modulate protein kinase activity, specifically the activity of serum and glucocorticoid regulated kinase (SGK), in particular of serum and glucocorticoid regulated kinase isoform 1 (SGK-1, SGK1), and are suitable for the treatment of diseases in which SGK activity is inappropriate, for example degenerative joint disorders or inflammatory processes such as osteoarthritis or rheumatism. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.